Literature DB >> 29202493

Health-Related Quality of Life and Mental Health in Primary Aldosteronism: A Systematic Review.

Marieke S Velema1, Aline H de Nooijer1, Vivian W G Burgers2, Ad R M M Hermus1, Henri J L M Timmers1, Jacques W M Lenders1,3, Olga Husson2, Jaap Deinum1.   

Abstract

The aim of this review was to determine the impact of primary aldosteronism on health-related quality of life (HRQoL) and mental health. We performed a systematic literature search up to July 2017 in six electronic databases. First, we screened the articles derived from this search based on title and abstract. Second, the selected studies were systematically reviewed and checked for our predefined inclusion criteria. The search yielded 753 articles, of which 15 studies met our inclusion criteria. Untreated patients with primary aldosteronism showed an impaired physical and mental HRQoL as compared to the general population. Multiple domains of HRQoL were affected. This applied to patients with both an aldosterone-producing adenoma and bilateral adrenal hyperplasia. Adrenalectomy improves HRQoL. Conflicting results have been reported on the extent of this improvement, the improvement after initiation of medical treatment, and whether there is a difference in HRQoL after both treatments. Similarly, psychopathological symptoms of anxiety, demoralization, stress, depression and nervousness were more frequently reported in untreated patients with primary aldosteronism than in the general population and patients with hypertension. Also an impaired sleep quality has been reported. Improvement of these symptoms was observed after treatment with both adrenalectomy and mineralocorticoid receptor antagonists. This review shows that HRQoL is impaired and psychopathology is more frequently reported in patients with primary aldosteronism. This seems to be at least partly reversible after treatment but the extent of improvement remains unknown. To assess HRQoL in these patients more precisely a primary aldosteronism-specific HRQoL questionnaire is required. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29202493     DOI: 10.1055/s-0043-121706

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  10 in total

Review 1.  The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment.

Authors:  Anand Vaidya; Paolo Mulatero; Rene Baudrand; Gail K Adler
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

Review 2.  Primary aldosteronism - a multidimensional syndrome.

Authors:  Adina F Turcu; Jun Yang; Anand Vaidya
Journal:  Nat Rev Endocrinol       Date:  2022-08-31       Impact factor: 47.564

3.  Aldosterone-sensitive HSD2 neurons in mice.

Authors:  Silvia Gasparini; Jon M Resch; Sowmya V Narayan; Lila Peltekian; Gabrielle N Iverson; Samyukta Karthik; Joel C Geerling
Journal:  Brain Struct Funct       Date:  2018-10-20       Impact factor: 3.270

4.  Quality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists.

Authors:  Yuichi Yoshida; Rika Yoshida; Kanako Shibuta; Yoshinori Ozeki; Mitsuhiro Okamoto; Koro Gotoh; Takayuki Masaki; Hirotaka Shibata
Journal:  J Endocr Soc       Date:  2021-02-16

Review 5.  Therapeutic Outcomes with Surgical and Medical Management of Primary Aldosteronism.

Authors:  Heather Wachtel; Douglas L Fraker
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 3.955

Review 6.  Top-down and bottom-up control of stress-coping.

Authors:  Edo R de Kloet; Sybren F de Kloet; Carien S de Kloet; Annette D de Kloet
Journal:  J Neuroendocrinol       Date:  2019-02-01       Impact factor: 3.627

7.  A disease-specific Quality of Life questionnaire for primary aldosteronism.

Authors:  Marieke Stientje Velema; Aline de Nooijer; Ad R M M Hermus; Henri J L M Timmers; Jacques W M Lenders; Olga Husson; Jaap Deinum
Journal:  Endocr Connect       Date:  2019-04       Impact factor: 3.335

8.  Steroid hormone secretion after stimulation of mineralocorticoid and NMDA receptors and cardiovascular risk in patients with depression.

Authors:  Jan Nowacki; Katja Wingenfeld; Michael Kaczmarczyk; Woo Ri Chae; Paula Salchow; Ikram Abu-Tir; Dominique Piber; Julian Hellmann-Regen; Christian Otte
Journal:  Transl Psychiatry       Date:  2020-04-20       Impact factor: 6.222

Review 9.  Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism.

Authors:  Xiao Lin; Muhammad Hasnain Ehsan Ullah; Xiong Wu; Feng Xu; Su-Kang Shan; Li-Min Lei; Ling-Qing Yuan; Jun Liu
Journal:  Front Cardiovasc Med       Date:  2022-02-02

10.  Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism.

Authors:  Minna Soinio; Anna-Kaarina Luukkonen; Marko Seppänen; Jukka Kemppainen; Janne Seppänen; Juha-Pekka Pienimäki; Helena Leijon; Tiina Vesterinen; Johanna Arola; Eila Lantto; Semi Helin; Ilkka Tikkanen; Saara Metso; Tuomas Mirtti; Ilkka Heiskanen; Leena Norvio; Mirja Tiikkainen; Tuula Tikkanen; Timo Sane; Matti Välimäki; Celso E Gomez-Sanchez; Ilkka Pörsti; Pirjo Nuutila; Pasi I Nevalainen; Niina Matikainen
Journal:  Eur J Endocrinol       Date:  2020-12       Impact factor: 6.664

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.